Search

Your search keyword '"Stephenson, Tara"' showing total 8 results
Start Over Author "Stephenson, Tara" Journal blood
8 results on '"Stephenson, Tara"'

1. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Author

Cortes-Selva, Diana, Perova, Tatiana, Skerget, Sheri, Vishwamitra, Deeksha, Stein, Sarah, Boominathan, Rengasamy, Lau, Onsay, Calara-Nielsen, Karl, Davis, Cuc, Patel, Jaymala, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Goldberg, Jenna, Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S., Moreau, Philippe, Usmani, Saad Z., Bahlis, Nizar J., van de Donk, Niels W. C. J., and Verona, Raluca I.

Published
2024
Full Text
View/download PDF

2. Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Author

Miao, Xin, primary, Wu, Liviawati S., additional, Wang Lin, Shun Xin, additional, Xu, Yan, additional, Chen, Yang, additional, Iwaki, Yuki, additional, Kobos, Rachel, additional, Stephenson, Tara, additional, Kemmerer, Kristy, additional, Uhlar, Clarissa M., additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Trancucci, Danielle, additional, Verona, Raluca, additional, Pei, Lixia, additional, Su, Yaming, additional, Ouellet, Daniele, additional, Garfall, Alfred L., additional, Krishnan, Amrita Y., additional, Usmani, Saad, additional, Girgis, Suzette, additional, and Zhou, Honghui, additional

Published
2022
Full Text
View/download PDF

3. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Author

Cortes-Selva, Diana, primary, Casneuf, Tineke, additional, Vishwamitra, Deeksha, additional, Stein, Sarah, additional, Perova, Tatiana, additional, Skerget, Sheri, additional, Ramos, Elena, additional, van Steenbergen, Laure, additional, De Maeyer, Dries, additional, Boominathan, Rengasamy, additional, Lau, Onsay, additional, Davis, Cuc, additional, Banerjee, Arnob, additional, Stephenson, Tara, additional, Uhlar, Clarissa M., additional, Kobos, Rachel, additional, Goldberg, Jenna D., additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Girgis, Suzette, additional, Wang Lin, Shun Xin, additional, Wu, Liviawati S., additional, Moreau, Philippe, additional, Usmani, Saad, additional, Bahlis, Nizar Jacques, additional, Van De Donk, Niels WCJ, additional, and Verona, Raluca, additional

Published
2022
Full Text
View/download PDF

4. Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Author

Moreau, Philippe, primary, Usmani, Saad Z., additional, Garfall, Alfred L., additional, van de Donk, Niels W.C.J., additional, Nahi, Hareth, additional, San-Miguel, Jesus, additional, Oriol, Albert, additional, Nooka, Ajay K., additional, Martin, Thomas, additional, Rosinol, Laura, additional, Chari, Ajai, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Mateos, Maria-Victoria, additional, Bahlis, Nizar J., additional, Popat, Rakesh, additional, Besemer, Britta, additional, Martínez-López, Joaquín, additional, Sidana, Surbhi, additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Verona, Raluca I., additional, Girgis, Suzette, additional, Olyslager, Yunsi, additional, Jaffe, Mindy, additional, Uhlar, Clarissa M., additional, Stephenson, Tara, additional, Van Rampelbergh, Rian, additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Kobos, Rachel, additional, and Krishnan, Amrita Y., additional

Published
2021
Full Text
View/download PDF

5. Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Author

Garfall, Alfred L., primary, Usmani, Saad Z., additional, Mateos, María-Victoria, additional, Nahi, Hareth, additional, van de Donk, Niels W.C.J., additional, San-Miguel, Jesus F., additional, Oriol Rocafiguera, Albert, additional, Rosinol, Laura, additional, Chari, Ajai, additional, Bhutani, Manisha, additional, Pei, Lixia, additional, Verona, Raluca, additional, Girgis, Suzette, additional, Stephenson, Tara, additional, Goldberg, Jenna D., additional, Banerjee, Arnob, additional, and Krishnan, Amrita, additional

Published
2020
Full Text
View/download PDF

6. Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients

Author

Girgis, Suzette, primary, Wang Lin, Shun Xin, additional, Pillarisetti, Kodandaram, additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Shetty, Shoba, additional, Stephenson, Tara, additional, Hilder, Brandi W., additional, Hanna, Brett, additional, Smit, Jennifer, additional, Adams III, Homer, additional, Sun, Yu-Nien (Tom), additional, Infante, Jeffrey R., additional, Elsayed, Yusri A, additional, and Sharma, Amarnath, additional

Published
2020
Full Text
View/download PDF

7. Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Author

Vishwamitra, Deeksha, Skerget, Sheri, Cortes, Diana, Perova, Tatiana, Lau, Onsay, Davis, Cuc, Guo, Yue, Miao, Xin, Stephenson, Tara, Hodin, Caroline, Uhlar, Clarissa, Trancucci, Danielle, Chastain, Katherine, Bahlis, Nizar J, Van De Donk, Niels W.C.J., and Verona, Raluca

Abstract

Introduction:Teclistamab (tec) is the only approved B-cell maturation antigen (BCMA) × CD3 bispecific antibody with a personalized, weight-based dosing schedule for the treatment of triple-class exposed relapsed/refractory multiple myeloma (RRMM). In the phase 1/2 MajesTEC-1 study (NCT03145181/NCT04557098), tec demonstrated deep and durable responses. To better understand mechanisms of resistance and relapse in MajesTEC-1, we assessed longitudinal BCMA expression and immune profiles.

Published
2023
Full Text
View/download PDF

8. Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment

Author

Zhou, Jia, Vishwamitra, Deeksha, Guo, Yue, Verona, Raluca, Perales Puchalt, Alfredo, Stephenson, Tara, Hodin, Caroline, Banerjee, Arnob, Chastain, Katherine, Haddish-Berhane, Nahor, and Wang, Weirong

Abstract

Introduction:Teclistamab is the only approved B-cell maturation antigen (BCMA) × CD3 bispecific antibody (BsAb) with personalized, weight-based dosing for the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM).In the MajesTEC-1 study (NCT03145181 and NCT04557098), the incidence of all grade (mostly grade 1 or 2) cytokine release syndrome (CRS) was 72.1% (Moreau et al. 2022). The cytokine interleukin-6 (IL-6) is found to be increased in the serum of patients with CRS (Shimabukuro-Vornhagen et al. 2018). Tocilizumab is a humanized IL-6 receptor-inhibiting monoclonal antibody. As a competitive antagonist, tocilizumab inhibits the IL-6 pathway by competing with IL-6 for binding to IL-6 receptor (IL-6R), resulting in lower IL-6R receptor occupancy (RO) by IL-6, thereby blocking IL-6 signaling. By blocking IL-6R, tocilizumab also reduces IL-6R-mediated IL-6 clearance, which leads to an increase in serum IL-6 levels (Uchiyama et al. 2008). It has been published previously that a single dose of prophylactic tocilizumab reduced the overall incidence of CRS to 26% after teclistamab administration, which represents a 64% reduction compared to the CRS incidence observed in MajesTEC-1 (van de Donk et al. 2023). A mechanism-based PK/PD model was used to evaluate the impact of tocilizumab prophylactic treatment on the soluble IL-6R (sIL-6R), IL-6 and the duration of the blockade of IL-6 signaling pathway in the patients following teclistamab treatment.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results